Document is current

Article History

Received: 18 April 2024

Accepted: 17 October 2024

First Online: 26 October 2024

Declarations

:

: Institutional review board (IRB) approval covering patient data contained in the OPERA database was received from Advarra IRB; a waiver of informed consent and authorization for the use of protected health information for patient data was granted (Pro00023648). The study was conducted in accordance with HIPAA and HITECH requirements, which expand upon the ethical principles detailed in the 1964 Declaration of Helsinki.

: Not applicable.

: GP, MBW, and AM are members of the Epidemiology and Clinical Advisory Board for Epividian. MBW has participated in post-conference advisory boards for the Conference on Retroviruses and Opportunistic Infections and International AIDS Conference and serves as a principal investigator on ViiV Healthcare clinical trials but does not receive personal compensation for this work, which goes directly to the AIDS Healthcare Foundation. AM receives research funding from Gilead, ViiV, GSK, Abbott, Roche, and Merck. He has attended advisory boards for Gilead, ViiV, and Epividian. JSF, LB, and GPF are employed by Epividian, Inc.; Epividian has had research funded by ViiV Healthcare, Merck & Co., Janssen, Gilead Sciences, Theratechnologies, EMD Serono, and AIDS Healthcare Foundation. VV, SS, CEH, and JvW are employed by ViiV Healthcare and hold stock in GSK as part of their employment.